SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -62.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -62.39% |
| Cost of Revenue | 12.61% | 1.55% | -202.28% | -6.00% | 565.02% |
| Gross Profit | -13.06% | -1.55% | 206.38% | -6.33% | -612.95% |
| SG&A Expenses | 90.48% | 6.62% | -24.91% | -25.65% | -78.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.78% | 12.11% | -7.00% | -12.67% | -47.22% |
| Operating Income | -57.56% | -12.11% | 4.60% | 5.43% | 46.97% |
| Income Before Tax | -47.97% | 539.11% | -37.88% | -3.40% | 50.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.97% | 539.11% | -37.88% | -3.40% | 50.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.97% | 539.11% | -37.88% | -3.40% | 50.15% |
| EBIT | -57.56% | -12.11% | 4.60% | 5.43% | 46.97% |
| EBITDA | -62.71% | -15.19% | 2.07% | -6.25% | 48.56% |
| EPS Basic | 95.16% | 144.80% | 194.51% | -2.85% | 63.73% |
| Normalized Basic EPS | 71.35% | 481.39% | -37.22% | -2.85% | 63.73% |
| EPS Diluted | 79.60% | 81.02% | 194.51% | -2.85% | 63.66% |
| Normalized Diluted EPS | 71.35% | 152.22% | -37.22% | -2.85% | 63.73% |
| Average Basic Shares Outstanding | 416.56% | 15.13% | 0.48% | 0.54% | 37.43% |
| Average Diluted Shares Outstanding | 416.56% | 740.93% | 0.48% | 0.54% | 37.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |